Keywords
Abstract
Modern predominant perception of the nanoscale lipid artefacts – liposomes as drug delivery systems (DDS), based on the ability of universal incorporation of active pharmaceutical ingredients (APhI). It was formed in the world process of creating and clinical application of more than 50 innovative liposomal drugs
for the treatment of oncological, infectious, inflammatory and other serious diseases. These include the original drugs Lipin, Lipodox, Lioliv and Lipoflavon created in Ukraine.
Along with the important role of liposomes as APhI provider, the concept of pharmacotherapeutic selfsufficiency of liposomes per se which was first proposed by academician A.V. Stefanov was convincingly confirmed. Antimicrobial, antiviral, anti-inflammatory, immunomodulatory and other manifestations of
pharmacological activity have been established for «empty» liposomes according to the variability of the phospholipid composition.
The drug «Lipin» is the most important evidence of the effectiveness and hugeness of clinical use of empty liposomes. The indicative experimental and clinical information on the pharmacotherapeutic use of Lipin in pulmonology, cardiology, nephrology, gynecology and obstetrics is presented. The possibility of
Lipin clinical positioning in dentistry, dermatology and radiation medicine is shown. The efficacy and safety of Lipin for systemic use in different clinic branches reflect the versatility of the mechanism of action of empty phospholipid liposomes with an emphasis on antioxidant, antihypoxic, membrane-protective and
immunomodulatory activity, pro-surfactant effect.
Attention is drawn to the potential of liposomes per se for implementing of the personalized medicine strategy and to the clinical advantages of the algorithm for the combined use of empty liposomes with DDS with the possibility of optimizing the clinical effect owing to the targeted differentiation of the phospholipid composition of liposomal partners.